Estelle Marrer-Berger, Ph.D.
Dr. Marrer-Berger leads 3T’s pre-clinical and translational science programs. She has 20 years of experience in the biopharmaceutical industry at Novartis Pharma AG and Roche. Dr. Marrer-Berger brings a wealth of expertise and leadership in drug safety, and nonclinical and translational development, with a proven track record of successful Investigational New Drug (IND) and Clinical Trial Authorization (CTA) filings in oncology and autoimmunity. Of note, she pioneered the use of Human Model Systems to support Entry into Human milestones for T-cell receptor (TCR)-based therapies, which earned global health authority approvals. Dr. Marrer-Berger received her Ph.D. in microbiology and immunology from the Université Louis Pasteur in Strasbourg, France.
